Section Arrow
AGEN.NASDAQ
- Agenus
Quotes are at least 15-min delayed:2024/05/07 16:59 EDT
Last
 12.005
-0.945 (-7.30%)
Day High 
13 
Prev. Close
12.95 
1-M High
14.24 
Volume 
1.27M 
Bid
11.94
Ask
12.65
Day Low
10.7 
Open
12.45 
1-M Low
4.775 
Market Cap 
271.88M 
Currency USD 
P/E -- 
%Yield
10-SMA 11.06 
20-SMA 9.02 
50-SMA 10.91 
52-W High 42.6 
52-W Low 4.775 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-13.80/-13.00
Enterprise Value
347.16M
Balance Sheet
Book Value Per Share
-7.64
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
156.31M
Operating Revenue Per Share
4.73
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CMNDClearmind Medicine1.48+0.31+26.50%-- 
DNAGinkgo Bioworks Holdings0.934-0.0541-5.48%-- 
JAGXJaguar Health0.2979-0.0191-6.03%-- 
FGENFibroGen1.36+0.2+17.24%-- 
LYRALyra Therapeutics0.43-0.0915-17.55%-- 
Quotes are at least 15-min delayed:2024/05/07 16:59 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.